Qynapse to Present Poster Presentations and Attend the Alzheimer’s Association International Conference (AAIC) 2021 in Denver, USA and Online

/0 Comments/in , /by

QYNAPSE Inc., a medical technology company commercializing an AI-powered and proprietary neuroimaging software platform, is attending the Alzheimer’s Association International Conference 2021 (AAIC) on July 26-30, 2021 in Denver, USA and online, and will present two poster presentations on QyScore®, it’s groundbreaking neuroimaging analysis platform for both clinical routine and clinical trial settings.

Read more

Qynapse to present clinical results of QyScore® for Alzheimer’s Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology

/0 Comments/in , /by

QYNAPSE today announced it will present clinical data on QyScore® for Alzheimer’s disease and multiple sclerosis at the 7th Congress of the European Academy of Neurology (EAN), which is being held virtually on June 19 – 22, 2021. Enrica Cavedo, PhD, Scientific Lead at Qynapse, will give an ePresentation on June 20, 2021, at 6:05 a.m. ET and Philippe Tran, R&D Scientist at Qynapse, will give an ePoster on June 20, 2021, at 1:30 p.m. ET.

Read more

QYNAPSE to Present at Sachs 4th Annual Neuroscience Innovation Forum

/0 Comments/in , /by

QYNAPSE is pleased to participate in the Sachs 4th Annual Neuroscience Innovation Forum (#Sachs_NIF) on April 28-30, 2021. Olivier Courrèges, CEO of QYNAPSE, is pleased to present QYNAPSE’s corporate vision on Day 1 of the Sachs 4th Annual Neuroscience Innovation Forum – which will be held virtually on Wednesday, April 28, 2021 at 2:20 p.m. ET.

Read more

QyPredict®: an AI prediction technology for optimizing patient selection in clinical trials to be presented at the CTAD Conference by QYNAPSE

/0 Comments/in , /by

QYNAPSE will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. The software computes a cognitive decline risk score that can be used to enrich patient selection strategy with the aim to increase clinical trial success probability.

Read more

Qynapse sponsors the 8th joint ACTRIMS-ECTRIMS meeting – MSVirtual2020

/0 Comments/in , /by

Qynapse is excited to participate in MSVirtual2020 to share and discuss innovative and cutting-edge research in the field of Multiple Sclerosis (MS). The latest QyScore® validation and performance advances will be presented during the conference.

Read more

Qynapse is pleased to participate in the 2020 Alzheimer’s Association International Conference virtual event

/0 Comments/in , /by

Qynapse is thrilled to be part of the Scientific Program of AAIC and the Virtual Exhibition from July 27 to July 31 − to present our latest advances and solutions.

Read more

Qynapse exhibits at the 2019 Alzheimer’s Association International Conference (AAIC) in Los Angeles, CA

/0 Comments/in /by

From July 14 – 18th, Qynapse will be part of the 2019 Alzheimer’s Association International Conference® (AAIC®) held in Los Angeles, California

Read more

Qynapse attended the 14th AD/PD International Conference

/0 Comments/in /by

Qynapse took part in the 2019 International Conference on Alzheimer’s & Parkinson’s Disease (AD/PDTM) in Lisbon, Portugal from March 26 – 31st

Read more

Qynapse exhibited at 2018 Alzheimer’s conference AAIC in Chicago

/0 Comments/in /by

From July 22– 26th, Qynapse took part in the 2018 Alzheimer’s Association International Conference® (AAIC®) held in Chicago, Illinois

Read more